You are now leaving Abacavir HSR Support. ViiV Healthcare does not recommend, endorse or accept liability for sites controlled by third parties.

Overview

The Abacavir Hypersensitivity Reaction (ABC HSR) educational programme has the following aims:

  • Maintaining low morbidity and mortality from ABC HSR in general, and to minimise the risk of ABC rechallenge in patients with clinically suspected HSR, regardless of HLA-B*5701 status.
  • Increase understanding and awareness of ABC HSR by Healthcare professionals (HCPs) and expand on the information already included in the product labels.
  • Increase awareness of ABC HSR by patients via the ABC HSR Alert/Warning card and product labelling.

Be aware

Understand HSR

Time to onset

Symptoms

Risk factors

Predicting HSR

The role of HLA-B*5701

HLA-B*5701 screening

Clinical data

Communicate

Ensure patients are informed in the event of a reaction

Diagnose

Clinical diagnosis

Consider the symptoms

Refer to the patient cases

Manage

In case of a suspected or confirmed abacavir HSR:
Withdraw abacavir
Monitor the patient

Never rechallenge

Rechallenge with abacavir can be fatal in confirmed or suspected HSR cases